A prospective observational study of Chemotherapy Induced Nausea Vomiting (CINV) in patients receiving Anthracycline based chemotherapy for Breast Cancer

Tata Memorial Centre0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年11月21日

试验速览

暂无简介。

•Breast cancer patients receiving first cycle of Anthracycline (Neo) Adjuvant chemotherapy
•Newly diagnosed Breast cancer patients requiring anthracycline regimens
•Patients with histologically confirmed invasive breast carcinoma.
•ECOG PS 0-2 at study entry
•Age more than 18 years

•Any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy could be completed
•Patients who had received or were to receive radiation therapy to the abdomen or pelvis in the week prior to treatment
•Patients who had vomited in the 24 hr prior to treatment or on concurrent intake of any other emetogenic drug or radiotherapy or a known hypersensitivity to 5-HT3-receptor antagonists or dexamethasone
•Patients who had an active infection or any uncontrolled disease other than malignancy
•Baseline laboratory values outside the clinically acceptable limits{Abnormal laboratory values (absolute neutrophil count <1,500/mm3, white blood cell count <3,000/mm3, platelet count <100,000/mm3, aspartate transaminase >2.5Ã? upper limit of normal, alanine transaminase >2.5Ã? upper limit of normal, bilirubin >1.5Ã? upper limit of normal, creatinine >1.5Ã? upper limit of normal}.
•Asymptomatic metastases to the brain
•Seizure disorder needing anticonvulsants unless clinically stable
•Intestinal obstruction

发起方